Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma

Authors :: Armand, Philippe
Zinzani, Pier Luigi
Lee, Hun Ju
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Herrera, Alex F.
Lin, Jianxin
Kim, Eunhee
Chakraborty, Samhita
Marinello, Patricia
Moskowitz, Craig H.
Source :: Blood; 20230101, Issue: Preprints
Publication Year :: 2023
Abstract: •Pembrolizumab monotherapy can produce very durable responses in a subset of patients with R/R cHL•Second-course pembrolizumab frequently reinduced sustained response in patients relapsing from CR

Full Text Access

Tools